68Ga-BNOTA-PRGD2 PET/CT in Healthy Volunteers and Lung Cancer Patients
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label dynamic whole-body PET/CT (positron emission tomography/computed
tomography) study for investigation of radiation dosimetry, plasma pharmacokinetics,
biodistribution, safety and diagnostic performance of 68Ga-BNOTA-PRGD2 in healthy volunteers
and lung cancer patients. A single dose of nearly 111 MBq 68Ga-BNOTA-PRGD2 ( ≤ 40 µg
BNOTA-PRGD2) will be intravenously injected into healthy volunteers and lung cancer patients.
Visual and semiquantitative method will be used to assess the PET/CT images. Changes of blood
pressure, pulse, respiration, temperature, routine blood and urine tests, serum alanine
aminotransferase, albumin, and creatinine, and any adverse events will be collected from the
volunteers. Adverse events will also be observed in the patients.